Vertex Analysts Lower Their Forecasts Following Q2 Results

Benzinga Earnings08-04 21:15

Vertex Inc (NASDAQ:VERX) reported upbeat earnings for the second quarter on Monday.

The company posted quarterly earnings of 20 cents per share which beat the analyst consensus estimate of 19 cents per share. The company reported quarterly sales of $203.970 million which beat the analyst consensus estimate of $202.296 million.

Vertex said it sees third-quarter sales of $208.000 million-$211.000 million, versus market estimates of $211.696 million.

“Vertex delivered solid second-quarter results, with revenue at the high end of our guidance and adjusted EBITDA exceeding our expectations,” said Christopher Young, President and Chief Executive Officer. “The quarter demonstrated the durability of our business and the earnings leverage we can generate through greater operating focus and discipline. Customer retention remained stable, and e-invoicing momentum improved as enterprises prepare for expanding global mandates and seek more comprehensive compliance solutions.”

Vertex shares fell 2% to $13.13 in pre-market trading.

These analysts made changes to their price targets on Vertex following earnings announcement.

Baird analyst Rob Oliver maintained the stock with an Outperform rating and lowered the price target from $19 to $17.
Stephens & Co. analyst Brett Huff maintained the stock with an Overweight rating and cut the price target from $20 to $18.
Canaccord Genuity analyst Michael Graham maintained the stock with a Buy and lowered the price target from $28 to $24.
BTIG analyst Clark Lampen downgraded the stock from Buy to Neutral.

Considering buying VERX stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656590955?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656590955","market":"us","top_or_hot":-1,"title":"Vertex Analysts Lower Their Forecasts Following Q2 Results","media":"Benzinga Earnings","content":"<html><body><p><strong>Vertex Inc</strong> (NASDAQ:VERX) reported upbeat earnings for the second quarter on Monday.</p>\n<p>The company posted quarterly earnings of 20 cents per share which beat the analyst consensus estimate of 19 cents per share. The company reported quarterly sales of $203.970 million which beat the analyst consensus estimate of $202.296 million.</p>\n<p>Vertex said it sees third-quarter sales of $208.000 million-$211.000 million, versus market estimates of $211.696 million.</p>\n<p>“Vertex delivered solid second-quarter results, with revenue at the high end of our guidance and adjusted EBITDA exceeding our expectations,” said Christopher Young, President and Chief Executive Officer. “The quarter demonstrated the durability of our business and the earnings leverage we can generate through greater operating focus and discipline. Customer retention remained stable, and e-invoicing momentum improved as enterprises prepare for expanding global mandates and seek more comprehensive compliance solutions.”</p>\n<p>Vertex shares fell 2% to $13.13 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Vertex following earnings announcement.</p>\n<ul>\n<li>Baird analyst Rob Oliver maintained the stock with an Outperform rating and lowered the price target from $19 to $17.</li>\n<li>Stephens &amp; Co. analyst Brett Huff maintained the stock with an Overweight rating and cut the price target from $20 to $18.</li>\n<li><a href=\"https://laohu8.com/S/CCORF\">Canaccord Genuity</a> analyst Michael Graham maintained the stock with a Buy and lowered the price target from $28 to $24.</li>\n<li>BTIG analyst Clark Lampen downgraded the stock from Buy to Neutral.</li>\n</ul>\n<p><strong>Considering buying VERX stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"317\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75-1024x317.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75-1024x317.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75-300x93.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75-768x238.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75.png 1147w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vertex Analysts Lower Their Forecasts Following Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVertex Analysts Lower Their Forecasts Following Q2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-08-04 21:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Vertex Inc</strong> (NASDAQ:VERX) reported upbeat earnings for the second quarter on Monday.</p>\n<p>The company posted quarterly earnings of 20 cents per share which beat the analyst consensus estimate of 19 cents per share. The company reported quarterly sales of $203.970 million which beat the analyst consensus estimate of $202.296 million.</p>\n<p>Vertex said it sees third-quarter sales of $208.000 million-$211.000 million, versus market estimates of $211.696 million.</p>\n<p>“Vertex delivered solid second-quarter results, with revenue at the high end of our guidance and adjusted EBITDA exceeding our expectations,” said Christopher Young, President and Chief Executive Officer. “The quarter demonstrated the durability of our business and the earnings leverage we can generate through greater operating focus and discipline. Customer retention remained stable, and e-invoicing momentum improved as enterprises prepare for expanding global mandates and seek more comprehensive compliance solutions.”</p>\n<p>Vertex shares fell 2% to $13.13 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Vertex following earnings announcement.</p>\n<ul>\n<li>Baird analyst Rob Oliver maintained the stock with an Outperform rating and lowered the price target from $19 to $17.</li>\n<li>Stephens &amp; Co. analyst Brett Huff maintained the stock with an Overweight rating and cut the price target from $20 to $18.</li>\n<li><a href=\"https://laohu8.com/S/CCORF\">Canaccord Genuity</a> analyst Michael Graham maintained the stock with a Buy and lowered the price target from $28 to $24.</li>\n<li>BTIG analyst Clark Lampen downgraded the stock from Buy to Neutral.</li>\n</ul>\n<p><strong>Considering buying VERX stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"317\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75-1024x317.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75-1024x317.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75-300x93.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75-768x238.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04091414/image-75.png 1147w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2468319806.SGD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/08/60906332/vertex-analysts-lower-their-forecasts-following-q2-results","article_id":"2656590955","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656590955","pubTimestamp":1785849333,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Vertex Inc (NASDAQ:VERX) reported strong Q2 earnings, exceeding analyst estimates. Sales for Q3 also expected to beat market estimates.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","VRTX":"福泰制药","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0566484027.USD":"安本美国小盘成长股","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BIB":"Ultra纳斯达克生物科","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","BK4567":"ESG概念","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4139":"生物科技","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","VERX":"Vertex, Inc.","LU0079474960.USD":"联博美国增长基金A","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BBH":"VanEck Biotech ETF","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","GNMX":"Corgi Genomics & Precision Medicine ETF","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4588":"碎股","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","IDNA":"iShares Genomics Immunology and Healthcare ETF","IBB":"生物科技指数ETF-iShares Nasdaq"},"translate_title":"Vertex 分析师在第二季度业绩公布后下调了预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDNA":0.6,"BBH":0.6,"TBXU":0.6,"BIB":0.6,"PBE":0.6,"GNMX":0.6,"VRTX":1.5,"IBB":0.6,"IBBQ":0.6,"VERX":1.5},"content_text":"Vertex Inc (NASDAQ:VERX) reported upbeat earnings for the second quarter on Monday.\nThe company posted quarterly earnings of 20 cents per share which beat the analyst consensus estimate of 19 cents per share. The company reported quarterly sales of $203.970 million which beat the analyst consensus estimate of $202.296 million.\nVertex said it sees third-quarter sales of $208.000 million-$211.000 million, versus market estimates of $211.696 million.\n“Vertex delivered solid second-quarter results, with revenue at the high end of our guidance and adjusted EBITDA exceeding our expectations,” said Christopher Young, President and Chief Executive Officer. “The quarter demonstrated the durability of our business and the earnings leverage we can generate through greater operating focus and discipline. Customer retention remained stable, and e-invoicing momentum improved as enterprises prepare for expanding global mandates and seek more comprehensive compliance solutions.”\nVertex shares fell 2% to $13.13 in pre-market trading.\nThese analysts made changes to their price targets on Vertex following earnings announcement.\n\nBaird analyst Rob Oliver maintained the stock with an Outperform rating and lowered the price target from $19 to $17.\nStephens & Co. analyst Brett Huff maintained the stock with an Overweight rating and cut the price target from $20 to $18.\nCanaccord Genuity analyst Michael Graham maintained the stock with a Buy and lowered the price target from $28 to $24.\nBTIG analyst Clark Lampen downgraded the stock from Buy to Neutral.\n\nConsidering buying VERX stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656590955","isCrawlerRequest":true}